Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Shattuck Labs (STTK)
NASDAQ:STTK
Holding STTK?
Track your performance easily
STTK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.07 - $11.76
Previous Close$1.18
Volume369.69K
Average Volume (3M)583.68K
Market Cap
$56.32M
Enterprise Value-$46.05M
Total Cash (Recent Filing)$105.34M
Total Debt (Recent Filing)$2.97M
Price to Earnings (P/E)―
Beta2.41
Next Earnings
Mar 18, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.85
Shares Outstanding47,727,269
10 Day Avg. Volume308,807
30 Day Avg. Volume583,680
Standard Deviation0.47
R-Squared0.04
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.54
Price to Sales (P/S)13.66
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-11.17
Enterprise Value/Gross Profit-27.79
Enterprise Value/Ebitda0.55
Forecast
1Y Price Target
$2.00Price Target Upside58.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Shattuck Labs News
PremiumCompany Announcements
Shattuck Labs Refocuses Strategy Amidst Restructuring and Cuts
Bulls Say, Bears Say
Bulls Say
Clinical TrialsA recent presentation at EHA '24 highlighted positive early updates from the ongoing Phase 1b HR-MDS/TP53 AML study, which included complete remission rates for both HR-MDS and TP53m AML patients treated with SL-172154 in combination with AZA that exceeded the expected complete remission rates for AZA alone.
Market PotentialWith increasing U.S. IBD prevalence and projected worldwide IBD sales reaching $26.8 billion by 2028, a favorable landscape is foreseen.
Pipeline DevelopmentShattuck emerges with autoimmune focused pipeline; introducing SL-325.
Bears Say
Competitive ChallengesCompetition will make development in IBD challenging with ~7 TL1A targeting programs in/or entering the clinic soon.
Pipeline ShiftThe company is pivoting away from oncology to develop newly-disclosed SL-325, a DR3 antibody intended for development in inflammatory bowel disease.
Product DiscontinuationResults from an interim OS analysis has led Shattuck to halt further development of '154.
---
Ownership Overview
19.32% Insiders
18.25% Mutual Funds
1.96% Other Institutional Investors
52.26% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
STTK FAQ
What was Shattuck Labs’s price range in the past 12 months?
Shattuck Labs lowest stock price was $1.07 and its highest was $11.76 in the past 12 months.
What is Shattuck Labs’s market cap?
Currently, no data Available
When is Shattuck Labs’s upcoming earnings report date?
Shattuck Labs’s upcoming earnings report date is Mar 18, 2025 which is in 116 days.
How were Shattuck Labs’s earnings last quarter?
Currently, no data Available
Is Shattuck Labs overvalued?
According to Wall Street analysts Shattuck Labs’s price is currently Undervalued.
Does Shattuck Labs pay dividends?
Shattuck Labs does not currently pay dividends.
What is Shattuck Labs’s EPS estimate?
Shattuck Labs’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shattuck Labs have?
Shattuck Labs has 47,727,270 shares outstanding.
What happened to Shattuck Labs’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Shattuck Labs?
Currently, no hedge funds are holding shares in STTK
---
Shattuck Labs Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.00 (58.73% Upside)
$2.00 (58.73% Upside)
Blogger Sentiment
Neutral
STTK Sentiment 50%
Sector Average 73%
Sector Average 73%
Insider Transactions
Bought Shares
Worth $44.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.86%
12-Months-Change
Fundamentals
Return on Equity
-68.48%
Trailing 12-Months
Asset Growth
-17.17%
Trailing 12-Months
Company Description
Shattuck Labs
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. The company's product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
---
STTK Earnings Call
Q3 2023
0:00 / 0:00
---
STTK Stock 12 Month Forecast
Average Price Target
$2.00
▲(58.73% Upside)
Technical Analysis
Best Analysts Covering STTK
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-57.52%
reiterated a buy rating 2 months ago
Copying Marc Frahm's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -57.52% per trade.
---